Health

Drug Trial Results Boost Eli Lilly

Updated 2026-10-28 13:50 UTC 1 source Positive

Eli Lilly announced that its investigational drug retatrutide outperformed Novo Nordisk’s Ozempic in a large diabetes study, showing greater effectiveness at lowering blood sugar and reducing weight.

Coverage timeline — 1 article

STAT News

STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.

2026-10-28 13:42 UTC